Core Points - Notified has launched a Chinese official website to enhance its presence in the Chinese market and provide local clients with easier access to its products and services [1][3] - The new website is designed specifically for Chinese users, featuring a user-friendly interface and comprehensive information about the company's business and updates [1][3] - Notified's president, Nimesh Davé, emphasized the importance of the Chinese market and the company's commitment to building deeper connections with local clients through this localized platform [1][3] Company Overview - Notified is a technology partner focused on serving investor relations (IR) and public relations (PR) professionals, aiming to help clients manage and disseminate corporate narratives [2] - The company offers an integrated PR and IR platform that simplifies various processes, including media outreach, press release distribution, performance analysis, and compliance reporting [2] - GlobeNewswire, a key component of Notified's services, is one of the largest and most trusted news distribution networks globally, serving leading institutions for over 30 years [2] Accessibility and Localization - The Chinese website ensures that clients can access detailed information in their native language, fostering a deeper understanding and trust [3] - The launch reflects Notified's commitment to addressing the unique needs of the Chinese market through localized communication and services [3] - Future plans include regular updates of Chinese content on the company's blog to provide additional value to users and potential clients regarding global trends and market analysis [3]

Core Viewpoint - JBT Marel (JBTM) is currently positioned as a more attractive investment compared to Thomson Reuters (TRI) based on various valuation metrics and Zacks Rank assessments [3][6]. Group 1: Zacks Rank and Earnings Outlook - JBTM has a Zacks Rank of 2 (Buy), indicating a positive earnings outlook, while TRI has a Zacks Rank of 4 (Sell), suggesting a weaker earnings outlook [3]. - The improvement in JBTM's earnings outlook is stronger than that of TRI, making it a more favorable option for value investors [3]. Group 2: Valuation Metrics - JBTM's forward P/E ratio is 21.38, significantly lower than TRI's forward P/E of 43.65, indicating that JBTM may be undervalued relative to TRI [5]. - The PEG ratio for JBTM is 2.49, while TRI's PEG ratio is 5.46, further suggesting that JBTM offers better value considering its expected earnings growth [5]. - JBTM has a P/B ratio of 2.56 compared to TRI's P/B of 6.37, reinforcing the notion that JBTM is more attractively priced based on its book value [6]. Group 3: Overall Value Assessment - JBTM holds a Value grade of B, while TRI has a Value grade of D, indicating that JBTM is perceived as a better value investment [6]. - The combination of a strong Zacks Rank and favorable valuation metrics positions JBTM as the preferred choice for value investors over TRI [2][6].

Group 1 - Futu Holdings Limited Sponsored ADR is part of the Business Services group, which includes 289 companies and ranks 8 in the Zacks Sector Rank [2] - The Zacks Rank for Futu Holdings is currently 1 (Strong Buy), indicating a positive outlook based on earnings estimates and revisions [3] - Over the past three months, the Zacks Consensus Estimate for Futu's full-year earnings has increased by 10.2%, reflecting improved analyst sentiment [4] Group 2 - Futu Holdings has achieved a year-to-date return of approximately 33%, outperforming the Business Services sector, which has returned an average of -0.5% [4] - In the Technology Services industry, which includes 151 stocks, Futu Holdings ranks 71 and has performed better than the average loss of 27.9% in the industry this year [6] - Another stock in the Business Services sector, Katapult Holdings, Inc., has a year-to-date return of 90.7% and a Zacks Rank of 2 (Buy) [5][6]

合作伙伴征集：2025全球手术机器人大会 报名：首届全球眼科大会 | 暂定议程 报名：首届全球心血管大会 | 奖项报名倒计时 报名：首届全球骨科大会 | 奖项报名倒计时 AI技术的飞速发展，为生物医药企业的研发、生产、销售等各个环节注入了强大的创新动力，助力企业在 激烈的市场竞争中脱颖而出。为了帮助生物医药企业管理者更好地把握这一趋势，深入探索AI技术在生物 医药领域的应用潜力，中关村联新生物医药联盟和IBM将举办一场生物医药行业开放日，诚邀生物医药产 业、医疗卫生产业领域人员拨冗出席。 活动时间： 2025年3月27日（周四）下午13:30-17:30 地点： IBM创新体验中心（具体地址报名审核后通知） 报名人数： 30人以内（报名有审核） https://docs.qq.com/form/page/DUHhPZExnZGhSUXhJ 或扫描下方二维码进行填写 IBM创新体验中心介绍： 开放日安排 1. AI创新解决方案体验之旅IBM最新、最前沿的AI创新解决方案，沉浸式体验让您感受AI技术如何为不 同行业带来颠覆性的变革，更有医药行业相关方案为您带来AI新启发。 2. 加速AI规模应用，释放数智生产力A ...

Core Points - ePlus has been recognized as F5's 2024 North America BeF5 Partner of the Year for its significant contributions to corporate social responsibility, community engagement, and customer success [1][3] - The award was presented at F5's AppWorld 2025 conference, which took place from February 25-27 in Las Vegas, highlighting partners that achieve meaningful business outcomes through innovative solutions and customer engagement [2] - ePlus's commitment to corporate social responsibility includes support for various initiatives such as NMDP, Habitat for Humanity, and the GRIT: Girls Re-Imagining Tomorrow® program, showcasing its role in leveraging technology for community betterment [3][4] Company Overview - ePlus is a customer-first, services-led industry leader providing transformative technology solutions across various sectors, including artificial intelligence, security, cloud, and data center services [5] - The company has over 2,200 employees and operates in multiple regions, including the United States, United Kingdom, Europe, and Asia-Pacific, with a focus on navigating business challenges for its clients [5]

Company Performance - Peraso reported a quarterly loss of $0.13 per share, better than the Zacks Consensus Estimate of a loss of $0.17, and a significant improvement from a loss of $8.52 per share a year ago, indicating an earnings surprise of 23.53% [1] - The company posted revenues of $3.68 million for the quarter ended December 2024, missing the Zacks Consensus Estimate by 3.21%, but showing growth from $1.83 million in the same quarter last year [2] - Over the last four quarters, Peraso has surpassed consensus EPS estimates two times and topped consensus revenue estimates two times [2] Stock Performance - Peraso shares have declined approximately 30.6% since the beginning of the year, contrasting with the S&P 500's decline of 4.5% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.30 on revenues of $3.38 million, and for the current fiscal year, it is -$1.60 on revenues of $13.25 million [7] Industry Outlook - The Technology Services industry, to which Peraso belongs, is currently ranked in the top 26% of over 250 Zacks industries, suggesting a favorable outlook compared to the bottom 50% [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Peraso's stock performance [5]

不同于上一代智慧城市以"城市大脑"为核心，联想"城市超级智能体"作为革新迭代产物，通过L3智 能体与多模态高效开源大模型技术的深度融合，能够有效支持限定范围内通用人工智能技术的实现。根 据联想集团的技术报告，城市超级智能体可使场景开发综合成本降低70%以上，极大推动了AI技术的普 惠化应用。 联想集团负责人表示，未来，公司将继续推动城市超级智能体在全国范围内的推广和应用，助力更 多城市实现智能化转型。 （文章来源：证券日报） 首个城市超级智能体项目落地武夷山 联想集团发力 智慧城市领域 近日，联想集团有限公司（以下简称"联想集团"）与武夷山市政府正式签署"武夷山城市超级智能 体"合作协议，标志着全球首个城市超级智能体项目在武夷山全面落地。作为人工智能技术与城市治理 深度融合的创新实践，该项目将依托联想集团全栈AI能力，整合武夷山文旅、茶产业等特色资源，构 建覆盖城市管理、民生服务、产业升级等层面的智能化中枢，为区域高质量发展注入科技动能。 联想集团高级副总裁、中国方案服务业务群总经理戴炜表示："联想将与武夷山市一起，以城市超 级智能体作为开启未来城市普惠AI新形态的钥匙，将AI能力源源不断输送给武夷山以文旅为 ...

合作伙伴征集：2025全球手术机器人大会 报名：首届全球眼科大会 | 暂定议程 报名：首届全球心血管大会 | 奖项报名倒计时 报名：首届全球骨科大会 | 奖项报名倒计时 AI技术的飞速发展，为生物医药企业的研发、生产、销售等各个环节注入了强大的创新动力，助力企业在 激烈的市场竞争中脱颖而出。为了帮助生物医药企业管理者更好地把握这一趋势，深入探索AI技术在生物 医药领域的应用潜力，中关村联新生物医药联盟和IBM将举办一场生物医药行业开放日，诚邀生物医药产 业、医疗卫生产业领域人员拨冗出席。 活动时间： 2025年3月27日（周四）下午13:30-17:30 地点： IBM创新体验中心（具体地址报名审核后通知） 报名人数： 30人以内（报名有审核） 开放日安排 1. AI创新解决方案体验之旅IBM最新、最前沿的AI创新解决方案，沉浸式体验让您感受AI技术如何为不 同行业带来颠覆性的变革，更有医药行业相关方案为您带来AI新启发。 2. 加速AI规模应用，释放数智生产力AI技术的价值不仅在于创新，更在于其能够大规模落地应用，为企 业创造实实在在的效益。在这一环节，IBM团队将分享企业如何构建自己的AI能力进行业务赋能 ...

Group 1 - Accolade (ACCD) has gained approximately 103.2% year-to-date, significantly outperforming the average return of 6.6% for the Business Services sector [4] - The Zacks Rank for Accolade is currently 2 (Buy), indicating a positive outlook based on earnings estimates and revisions [3] - The Zacks Consensus Estimate for Accolade's full-year earnings has increased by 1.4% over the past three months, reflecting improved analyst sentiment [3] Group 2 - Accolade is part of the Technology Services industry, which consists of 151 stocks and is currently ranked 68 in the Zacks Industry Rank, with an average gain of 4.8% year-to-date [5] - Casella (CWST), another stock in the Business Services sector, has returned 7.5% year-to-date and also holds a Zacks Rank of 2 (Buy) [4][5] - The Waste Removal Services industry, to which Casella belongs, is ranked 148 and has seen a year-to-date increase of 10.8% [6]

Group 1 - Xperi reported quarterly earnings of $0.39 per share, exceeding the Zacks Consensus Estimate of $0.28 per share, and showing a significant increase from $0.11 per share a year ago, resulting in an earnings surprise of 39.29% [1] - The company posted revenues of $122.36 million for the quarter ended December 2024, slightly missing the Zacks Consensus Estimate by 0.02%, and down from $137.23 million year-over-year [2] - Over the last four quarters, Xperi has surpassed consensus EPS estimates three times and topped consensus revenue estimates two times [2] Group 2 - Xperi shares have underperformed the market, losing about 16% since the beginning of the year, while the S&P 500 has gained 1.3% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the coming quarter is $0.18 on revenues of $116.28 million, and for the current fiscal year, it is $0.90 on revenues of $480.15 million [7] Group 3 - The Zacks Industry Rank indicates that the Technology Services sector is currently in the top 28% of over 250 Zacks industries, suggesting a favorable outlook compared to the bottom 50% [8] - The estimate revisions trend for Xperi is mixed, resulting in a Zacks Rank 3 (Hold), indicating that shares are expected to perform in line with the market in the near future [6]